Ascletis Pharma Inc., a Chinese biopharmaceutical company, is scheduled to present data on multiple drug candidates for obesity at the 33rd European Congress on Obesity (ECO 2026). The congress will take place in Maastricht, Netherlands, from May 12 to 15, 2026.
The company announced on May 6, 2026, that its presentations will include preclinical and clinical data on ASC30, a once-monthly subcutaneous injection for obesity, and ASC47, a novel oral drug candidate. These programs target the GLP-1 receptor and other metabolic pathways.
Ascletis aims to address the growing global obesity epidemic, which affects over 650 million adults worldwide according to the World Health Organization. The company's research focuses on developing more convenient and effective treatments.
Details of the specific data to be presented have not been fully disclosed, but the company expects to share results from ongoing Phase I and Phase II trials. The ECO 2026 congress is a key event for obesity research, bringing together scientists and clinicians from around the world.
